IDM Pharma Reports First Quarter Financial Results
...ollaboration agreement with sanofi-aventis for the uvidem program. As a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem were recognized after the first quarter of 2008. ...IDM Pharma Reports First Quarter Financial Results
... a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem will be recognized after this quarter. Research and development (R&D) exp...IDM Pharma Reports 2007 Financial Results
...ult of the decision by sanofi-aventis to terminate its participation in the uvidem development program in December 2007. Cash and cash equivalents was $28.4 m...fi-aventis' decision in December 2007 to terminate its participation in the uvidem development program. Interest income increased to $0.4 million for the th...IDM Pharma Reports Third Quarter 2007 Financial Results
...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...6. The spending related to clinical development of uvidem and clinical development, regulatory filings and m...IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
... IDM Pharma, Inc. today presented preliminary results from a Phase II uvidem (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and induction of immune respon...IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
...annual meeting in Chicago on June 1-5 2007. uvidem presentation details: -- "Clinical and immu...gned to assess the safety and clinical activity of uvidem in patients with stage III or IV melanoma with mea...atient enrolled in March 2006. About UVIDEM(R) uvidem is a therapeutic specific immunostimulant develope...IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
... - Results show uvidem was well-tolerated with signs of durable disease c...inical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and i...arance of anti-TAA specific CD8+ T cells. -- uvidem was well tolerated with toxicity limited to mild e...IDM Pharma Reports 2008 Financial Results
...is' decision to terminate its participation in the uvidem development program in December 2007, we will not ... reduction in spending on MEPACT (mifamurtide) and uvidem development, as well as reductions associated with...ecember 2007 to terminate its participation in the uvidem development program. The $3.5 million includes $3...